These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36970122)

  • 1. The Allelic Expression of RNA Editing Gene
    Zeng J; Han L; Wang T; Huang L; Zheng Y; Zhang N; Li Z; Yang M
    Pharmgenomics Pers Med; 2023; 16():229-238. PubMed ID: 36970122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma.
    Song Y; Xing H; Zhou L; Zhang N; Yang M
    Arch Toxicol; 2021 Sep; 95(9):3063-3070. PubMed ID: 34251499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N6-methyladenosine reader YTHDC2 and eraser FTO may determine hepatocellular carcinoma prognoses after transarterial chemoembolization.
    Liu J; Wang D; Zhou J; Wang L; Zhang N; Zhou L; Zeng J; Liu J; Yang M
    Arch Toxicol; 2021 May; 95(5):1621-1629. PubMed ID: 33713148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RNA editing enzyme ADAR modulated by the rs1127317 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Hua H; Zeng J; Xing H; He Y; Han L; Zhang N; Yang M
    Life Sci; 2022 May; 296():120408. PubMed ID: 35202641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma.
    Li W; Wang T; Fu G; Xu Y; Zhang N; Han L; Yang M
    Endocr Relat Cancer; 2023 Jan; 30(1):. PubMed ID: 36305508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative Functional Genomics Implicated the Key T-/B-Cell Deficiency Regulator
    Xu Y; Wang T; Zeng J; Wang B; Zhou L; Yang M; Zhang L; Zhang N
    Front Cell Dev Biol; 2021; 9():720791. PubMed ID: 34646823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.
    Wei X; Zhao L; Ren R; Ji F; Xue S; Zhang J; Liu Z; Ma Z; Wang XW; Wong L; Liu N; Shi J; Guo X; Roessler S; Zheng X; Ji J
    Hepatology; 2021 Apr; 73(4):1381-1398. PubMed ID: 32609900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.
    Manjunatha N; Ganduri V; Rajasekaran K; Duraiyarasan S; Adefuye M
    Cureus; 2022 Aug; 14(8):e28439. PubMed ID: 36176866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Variants in ASCT2 Gene are Associated with the Prognosis of Transarterial Chemoembolisation-Treated Early- Stage Hepatocelluar Carcinoma.
    Ge NJ; Shi ZY; Yu XH; Huang XJ; Wu YS; Chen YY; Zhang J; Yang YF
    Asian Pac J Cancer Prev; 2015; 16(9):4103-7. PubMed ID: 25987094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Evaluation of the Effects of RNA-Editing Proteins ADAR and ADARB1 on the Expression of the Drug-Metabolizing Enzymes in HepaRG Cells.
    Collins JM; Wang D
    Drug Metab Dispos; 2023 Nov; 51(11):1508-1514. PubMed ID: 37532539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
    Bettinger D; Spode R; Glaser N; Buettner N; Boettler T; Neumann-Haefelin C; Brunner TB; Gkika E; Maruschke L; Thimme R; Schultheiss M
    BMC Gastroenterol; 2017 Aug; 17(1):98. PubMed ID: 28797231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
    Soliman MH; Ragheb MA; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
    Anticancer Agents Med Chem; 2021; 21(2):246-253. PubMed ID: 32416702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preintervention MCP-1 serum levels as an early predictive marker of tumor response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    You R; Jiang H; Xu Q; Yin G
    Transl Cancer Res; 2021 Feb; 10(2):966-976. PubMed ID: 35116424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Guo Z; Wang J; Li L; Liu R; Fang J; Tie B
    World J Clin Cases; 2020 Aug; 8(16):3493-3502. PubMed ID: 32913856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma.
    Liu J; Yan J; Zhou C; Ma Q; Jin Q; Yang Z
    Tumour Biol; 2015 Jan; 36(1):219-25. PubMed ID: 25230788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Useful genes for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma.
    Guo Y; Hu H; Xu S; Xia W; Li H
    J Cancer Res Ther; 2022 Dec; 18(7):1860-1866. PubMed ID: 36647943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.